Senate confirms Crawford to lead FDA

Share this article:
The Senate acted last night to approve Dr. Lester Crawford's nomination as commissioner of the FDA. The vote, 78-16 in favor of the nomination, caps a months-long delay caused by a dispute over approval of the emergency contraceptive Plan B and an investigation into allegations that Crawford had an affair with a colleague.
"Dr. Crawford is a dedicated public servant who has ably led the agency over the last year and previously served as deputy commissioner," said Secretary of Health and Human Service Mike Leavitt. "I look forward to working with Dr. Crawford and FDA as we seek to continue advancing the nation's health."
Leavitt said last week that FDA would make a decision on switching Barr Laboratories' emergency contraceptive Plan B to OTC status by Sept. 1st.
Democratic Sens. Patty Murray of Washington and Hillary Clinton of New York then announced that they would lift a "hold" they had placed on Crawford's nomination, which had effectively prevented a vote.
The senators, however, said they continue to have "concerns about the lack of leadership and independent decision-making that Dr. Crawford and the FDA have shown in this case."
The nomination also was delayed several weeks by accusations that Crawford was carrying on an affair with someone in his office, but an investigation turned up no evidence.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...